Alvotech: High-Growth Pure-Play in Biosimilars with Cautious Upside Amid Execution Risks
Overview
Alvotech SA is a global, founder-led biopharma company focused on developing and manufacturing biosimilar drugs—reduced-cost versions of major biologics losing exclusivity. With a robust pipeline targeting autoimmune, oncology, and ophthalmology markets, Alvotech transitioned in 2024 into a revenue-generating commercial enterprise, driven by high-demand products like its Humira and Stelara biosimilars. Its unique model integrates in-house R&D, manufacturing, and a powerful distribution partnership web, enabling rapid, broad market access. Alvotech is positioned as a leader in the burgeoning biosimilars sector and seeks to deliver affordable biologics at scale globally.